dstock, I think Crash is correct.
DCVax-L is produced by a patented process which converts monocytes into dendrocytes. According to Chat GP;
Dendrocytes are produced in vitro by incubating the monocytes with a brew of GM-CSF, IL4, TNF-a, IL1-ß, IL6 and Prostaglandin E2 which converts them into dendrocytes. These are then incubated with tumour lysate to programme them against the tumour antigens after which the sensitised dendrocytes are separated off, put into ampoules and cryopreserved until required.
The article in Clinical Cancer Research (July 2016) outlines the production method for the dendrocytes and the vaccine used in the study as well as the protocol for the administration of the vaccine. Although both vaccines were administered intradermally at the same sort of intervals, if Chat GPT (above) is accurate, there are several differences between the 2 production methods and administration of the vaccines..
The monocytes in the study were produced in vitro by incubating the monocytes with GM-CSF, IL4, Interferon-?, and clinical grade lipopolysaccharide. One aliquot of the Dendrocytes was pulsed with tumor lysate and the second pulsed with "Keyhole Limpet Hemocyanin" before the 2 aliquots were combined at 1:1 ratio to comprise each DC vaccine.
All vaccines were administered immediately after manufacturing was completed; none were cryopreserved. As with DCVax-L the vaccine doses were administered intradermally but, in addition, "CYT107" (recombinant human IL-7) was administered subcutaneously on days 0, 14, 28 and 42.
It seems to me that there are sufficient differences in the ingredients of the magic potions used in the the 2 protocols to preclude the 2016 study being with DCVax-L (as we know it).
AI
Market Data 
Markets 
